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Abstract
Background/Objective: The diagnosis of tuberculous meningitis (TBM) in resource poor TB endemic environments is
challenging. The accuracy of current tools for the rapid diagnosis of TBM is suboptimal. We sought to develop a clinical-
prediction rule for the diagnosis of TBM in a high HIV prevalence setting, and to compare performance outcomes to
conventional diagnostic modalities and a novel lipoarabinomannan (LAM) antigen detection test (Clearview-TBH) using
cerebrospinal fluid (CSF).
Methods: PatientswithsuspectedTBMwereclassifiedasdefinite-TBM(CSFcultureorPCRpositive),probable-TBMandnon-TBM.
Results: Of the 150 patients, 84% were HIV-infected (median [IQR] CD4 count=132 [54; 241] cells/ml). There were 39, 55 and
54 patients in the definite, probable and non-TBM groups, respectively. The LAM sensitivity and specificity (95%CI) was 31%
(17;48) and 94% (85;99), respectively (cut-point $0.18). By contrast, smear-microscopy was 100% specific but detected none
of the definite-TBM cases. LAM positivity was associated with HIV co-infection and low CD4 T cell count (CD4,200 vs. .200
cells/ml; p=0.03). The sensitivity and specificity in those with a CD4,100 cells/ml was 50% (27;73) and 95% (74;99),
respectively. A clinical-prediction rule $6 derived from multivariate analysis had a sensitivity and specificity (95%CI) of 47%
(31;64) and 98% (90;100), respectively. When LAM was combined with the clinical-prediction-rule, the sensitivity increased
significantly (p,0.001) to 63% (47;68) and specificity remained high at 93% (82;98).
Conclusions: Despite its modest sensitivity the LAM ELISA is an accurate rapid rule-in test for TBM that has incremental
value over smear-microscopy. The rule-in value of LAM can be further increased by combination with a clinical-prediction
rule, thus enhancing the rapid diagnosis of TBM in HIV-infected persons with advanced immunosuppression.
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Introduction
Although the tuberculosis (TB) epidemic has plateaued in
several regions of the world, in Africa, fuelled by poverty and HIV
co-infection, TB is out of control. South Africa has the fifth highest
burden of TB and the largest number of HIV-infected residents in
any one country worldwide [1]. Given the high rate of HIV-TB
co-infection, extra-pulmonary TB (EPTB) and hence central
nervous system TB, which comprises 1 to 18% of EPTB [2,3,4,5],
is a common clinical problem.
HIV-infected patients with TB meningitis (TBM) are particu-
larly challenging to manage because there are no accurate tools to
rapidly establish a diagnosis and delay in establishing treatment is
associated with mortality [6,7,8]. Smear-microscopy in an ideal
research setting, and using high volumes of processed CSF, may
have a modest sensitivity [8,9]. However, in a programmatic
setting in Africa the yield is dismal and recent studies in HIV-
infected populations reveal a sensitivity of less than 5% [10].
Polymerase chain reaction (PCR), which may be used as a
confirmatory test for TBM [11], is a good rapid rule-in test for
TBM with a sensitivity of ,40 to 50% but this technology is
unavailable in most hospitals in Africa [12]. We recently showed
that CSF antigen-specific quantitative T cell assays may be a rapid
and accurate rule-in test for TBM but the available ELISPOT
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[13]. The initial promise of antibody [8,14,15] and antigen-based
[16,17,18] tests for TBM have not been sustained. Given the poor
performance of diagnostic tools we attempted to devise a clinical
prediction rule, hitherto unavailable, suited to resource-poor high
HIV prevalence settings.
Very recently a standardised lipoarabinomannan (LAM) antigen-
detection ELISA test, which yields a result within 2 to 3 hours, has
been developed (ClearviewH TB ELISA, ME, USA; see http://
www.clearview.com/tb_elisa.aspx) and is useful for the diagnosis of
TB in HIV-infected persons with advanced immunosuppression
[19,20,21]. Although tested mainly in urine [22,23,24,25,26], we
recently evaluated this assay in a proof-of-concept study using CSF
from patients with suspected TBM[27]. Given thepromising results
in CSF [27] we performed a prospective study using the LAM
Clearview TBH ELISA test in a predominantly HIV-infected
population. To our knowledge there are no previous reports
evaluatingthisassayinCSF.A particularlyinterestingfeature ofthis
technology, which highlights the broader significanceof this work,is
thata point-of-care (POC)lateralflowassayhasbeendeveloped and
is currently being evaluated in clinical trials [21].
Methods
Patient recruitment and processing
One hundred and fifty consecutive patients were prospectively
recruited over a period of 15 months, between January 2008 and
April 2009, at Inkosi Albert Luthuli Central Hospital (IALCH), a
tertiary referral center in Durban, South Africa. This study was
approved by the biomedical research ethics committee of the
University of KwaZulu-Natal. Patients presenting with a menin-
geal illness indicating the need for a lumbar puncture (LP) were
recruited from referring regional hospitals. Detailed recruitment
and patient processing methods were recently described [28].
Informed written consent was obtained from all patients (in
patients who were unable provide consent at initial presentation,
due to an abnormal mental state, consent was obtained from a first
degree relative or from the Head of Department when a lumbar
puncture was clinically justified) [29]. After excluding contraindi-
cations to a lumbar puncture (LP), CSF samples were processed
for microscopy (auramine staining of centrifuged samples using a
mercury vapour fluorescent microscope), Mycobacterium tuberculosis
(M.tb), bacterial, and fungal culture, and tests were performed to
exclude other locally prevalent causes of meningitis including
microscopy (Gram stain and for acid-fast bacilli), routine chemistry
(protein, glucose, chloride), TB PCR (Roche Amplicor, Roche
Diagnostics GmbH, Roche Applied Science, 68298 Mannheim,
Germany), viral PCR (Roche Amplicor) for [cytomegalovirus
(CMV), herpes simplex (HSV type 1) and varicella zoster virus
(VZV)], fluorescent treponemal antibody (FTA) test and venereal
disease research laboratory (VDRL) for neurosyphilis if FTA was
positive, cysticercal enzyme linked immunosorbent assay (ELISA),
and a cryptococcal antigen latex agglutination test (CLAT) which
has a high specificity and sensitivity. Detailed methods were
described in a previous publication [28]. Blood for CD4 counts
was taken and HIV status noted in all patients. Clinical
information recorded included demographic information, dura-
tion of symptoms and anti-tuberculous therapy, HIV status,
duration of steroid therapy, past history of tuberculosis and history
of tuberculosis (TB) contact.
Categorisation of patients
Patients were categorised as definite TBM (either CSF culture
or PCR positive for M.tb) [11], probable TBM (clinical features of
meningitis, an LP consistent with an aseptic bacterial meningitis,
negative for other causes of meningitis, and two of the following: a
chest X-ray consistent with active PTB, a CT scan consistent with
TBM (basal enhancement or hydrocephalus), and a response to
anti-tuberculous therapy), or non TBM (an alternate definite cause
for meningitis identified and response to appropriate non-
tuberculous therapy) [11,30]. The reference standard was thus
PCR or culture positivity for M. tb [11].
The laboratory technician was blinded to the clinical diagnosis
and clinician blinded to the laboratory result. Tests were done in
duplicate. Standard curves were derived by serial dilution of LAM
antigen using CSF from a patient with benign intracranial
hypertension.
Laboratory processing
CSF samples were processed for the detection of M.tb using a
standardized PCR assay (Roche AMPLICOR) as per manufac-
turer instructions. LAM antigen was measured using an ELISA kit
(ClearviewH TB ELISA, Inverness Medical Innovations, USA).
The samples were thawed and allowed to equilibrate to room
temperature. After an initial heating step (95–100uC for 30 min) to
separate antigen-antibody complexes, CSF samples (0.2 mls) were
seeded, in duplicate, into 96 well plates coated with anti-LAM
antibodies. Following this an ELISA was done to measure optical
density (OD) determined by a trained technician blinded to patient
details. The LAM OD values were extrapolated from a standard
curve constructed from two-fold serial dilutions (8 in total ranging
from 10 to 0.08 mg/ml) of the LAM antigen (20 mg/ml) in CSF
(Inverness Medical Innovations, USA).
Statistical Analysis
Chi square tests or Fisher exact tests were used to compare
categorical variables between TBM and non TBM patients.
Numeric variables were compared using a t-test or Wilcoxin Rank
sum test/or Kruskal Wallis test if normality could not be assumed.
Diagnostic performance, including 95% confidence intervals was
assessed using sensitivity, specificity, agreement (proportion in
whom both sample-specific results were concordant), predictive
values and area under the receiver operating characteristic (ROC)
curve where the combined results of culture or PCR was used as
the gold standard to classify patients as definite TBM or non
TBM. Three cut-off points were used: the laboratory standard,
Youden index [31] and maximum specificity.
A clinical index was generated using a stepwise logistic
regression model. Continuous variables such as clinical and
laboratory parameters were dichotomised using ROC curves to
identify cut-off points which maximised specificity prior to
inclusion in the model. Rounded b-coefficients from the reduced
model of significant variables were used to create a weighted
clinical index. The index was then dichotomised and the sensitivity
and specificity calculated. The sensitivity and specificity were
recalculated using the revised clinical plus LAM index. A one
sample z statistic was used to determine if adding LAM to the
clinical index resulted in a significant change in diagnostic
performance.
Results
Patient characteristics
Of the 150 consecutively recruited patients, two patients were
excluded (in 1 patient no definite diagnosis made and in one other
no CSF obtained). Thus, 148 samples were processed for LAM
antigen (39 definite TBM [31 culture positive, 8 additional PCR
positive patients), 55 probable TBM and 54 non TBM; Figure 1.
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culture positive patients. 84% of the cohort was HIV-infected,
13.5% HIV uninfected, 5% declined HIV testing. The median
inter-quartile range (IQR) CD4 count was 132 cells/ml (54;241).
Socio-demographic and a comparison of CSF findings between
definite TBM and non-TBM groups findings are shown in Table 1.
Alternate diagnoses in the non TBM group included cryptococcal
meningitis (n=30), bacterial meningitis (n=5), viral meningitis
(n=14; 4 VZV, 1 CMV, 9 unknown), neoplastic meningitis
(n=2), mucormycosis (n=1), venous sinus thrombosis with CSF
change (n=1), and neurosyphilis (n=1)
LAM antigen detection test outcomes
Performance outcomes were derived using the manufacturer’s
recommended cut-point (OD value of 0.1295), an optimal cut-
point using Youden’s index (a point on the ROC curve yielding
maximal sensitivity matched with the corresponding specificity)
and the AUC-derived cut point selecting for high specificity at the
expense of sensitivity. Outcomes are shown when the definite
TBM group (n=39) was compared to: (i) the entire non TBM
group; i.e. including patients with cryptococcal, acute bacterial
and other causes mentioned above (n=54; Table 2A), (ii) non-
TBM patients who were Gram stain or CLAT positive (n=35;
Table 2B), and (iii) non-TBM patients who were Gram stain or
CLAT negative (n=19; Table 2C). Thus, to evaluate whether
other simultaneously used rapid tests impacted on test findings, we
determined results for 3 different cut points in each of the
categories specified. We selected a cut-point of $0.18 because a
high specificity and moderate sensitivity defined a clinically useful
rule-in test; Table 2. Figure 2 illustrates the comparison between
definite and non TBM groups (unselected) and when the non
TBM group was split into CLAT and Gram stain positive samples,
and CLAT and Gram stain negative with the corresponding ROC
curves.
When the definite and probable TBM groups were combined
and compared to the non TBM, and using the cut-point of
$0.18 mg/ml, the outcome data were as follows: sensitivity 14%
(95% CI:8,23), specificity 94% (95% CI: 85,99), PPV 81% (95%
CI: 54;96), NPV 39% (95% CI: 31;48) and agreement 44% (95%
CI: 36;52). When these LAM data were combined with the clinical
index at a cut point of $6, the sensitivity and agreement improved
significantly to 38% (95% CI: 28;49, p= ,0.0001) and 58% (95%
CI: 50;66, p=0.01), respectively. The specificity, PPV and NPV
was 93% (95% CI: 82;98), 90% (95% CI: 76;97) and 47% (95%
CI: 37;57), respectively.
There were 19 patients in the non-TBM group in whom the
LAM antigen was positive using the OD value of 0.1295 as the
cut-point. Of this group 14 patients had cryptococcal meningitis
and 5 patients had viral meningitis. Given that patients were
transferred out to referring hospitals upon improvement no
comprehensive follow-up information was available for these
patients. Twelve patients in the definite TBM group were negative
for LAM antigen detection.
Relationship to CD4 count
When patients were stratified according to CD4 count, there
was a greater likelihood of definite TBM when the CD4 count was
,100 cells/ml versus $100 cells/ml; p=0.01; Table 3. A
comparison of CD4 counts ,200 to $200 cells/ml also showed
significance; p=0.03. No significant difference was seen when
sensitivity was compared in the in the HIV-infected and HIV
uninfected groups (p=0.3; Table 3). However, there were very few
patients in the HIV negative group.
There was no distinction when comparing probable TBM and
non TBM groups when stratified according to a CD4 count ,100
cells/ml versus $100 cells/ml; p=0.4.
Derivation of a clinical prediction rule and comparison to
CSF LAM levels
We derived a clinical index using univariate and multivariate
analysis (shown in Table 4). Factors significantly associated with a
diagnosis of TBM in the multivariate analysis were CSF to serum
glucose ratio, lymphocyte count, CD4 count and a negative CLAT
result. The clinical prediction rule was then calculated using the
Figure 1. Summary flow chart of patient categorisation and investigations performed at recruitment.
doi:10.1371/journal.pone.0015664.g001
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examined using various cut-points for the diagnosis of TBM. The
cut-point of $6 provided the best rule-in value. Table 5 shows
outcome data using the clinical prediction rule alone and when the
clinical prediction rule was combined with the LAM result: there
was a significant improvement in sensitivity (31% to 63%; p=
,0.001) and agreement (68% to 80% (p=0.01) but specificity
remained high at 93%.
Comparison of rapid tests for the diagnosis of TBM
Three tests were applied for a rapid diagnosis. When examining
for yield for rapid diagnosis using only culture positive patients as
the denominator (n=31 of the 39 definite TBM patients) the
yields for smear microscopy, LAM and PCR were, 0 (0%), 9 (29%,
at cut-point $0.18) and 14 (45%), respectively. Thus, there was a
significantly improved yield over smear microscopy when using
both LAM (p,0.001) and PCR (p= ,0.001). There was no
significant difference between the LAM and PCR yield (p=0.22).
Discussion
This study has three major findings. Firstly a newly developed
clinical prediction rule, suited to resource-poor high HIV
prevalence settings, is a useful rule-in test for the rapid diagnosis
of TBM. Secondly, LAM antigen, which has not previously been
prospectively evaluated in CSF, is useful as a rapid rule-in test for
the diagnosis of TBM in HIV-infected individuals with advanced
immunosuppression. Thirdly, combining the prediction rule with
LAM antigen detection further increases the rule-in value for TBM.
Table 1. Comparison of the clinical and laboratory parameters in the definite TB meningitis (culture or PCR positive; n=39) and
non TB meningitis (n=54) groups.
Characteristic Definite TBM (%) [IQR] Non TBM (%) [IQR] P value
n( % ) n( % )
Number 39 (42%) 54 (36%) 0.7
Mean age (6S.D) 33.5 (9.5) 32.9 (9.7) 0.7
Age
,36/$36 years
* 24/15 (61.5/38.5) 35/19 (29.6/70.4) 0.7
Sex
Male/Female 18/21 (46.2/53.9) 16/38 (29.6/70.4) 0.1
Ethnic Group
BA/M/E/I 38/1/0/0 (97.4/2.6/0/0) 53/0/0/1 (98.2/0/0/1.9) 0.3
HIV status
P/N/Unknown 34/4/1 (87.2/10.3/2.6) 47/6/1(87.0/11.1/1.9)
Previous TB
Yes/No/Unknown 8/27/4 (20.5/69.2/10.3) 24/30/0 (44.4/55.6/0) 0.007
TB contact (within 2 years)
Yes/No/Unknown 9/26/4 (23.1/66.7/10.3 14/40/0 (25.9/74.1/0) 0.06
Duration of illness (days)
,6/$6 days
* 6/31 (16.2/83.8) 9/45 (16.7/83.3) 0.9
Steroid treatment
Yes/No 12/27 (30.8/69.2) 8/46 (14.8/85.2) 0.07
CLAT
Yes/no 4/35 (10.3/89.7) 27/27 (50/50) ,0.001
CD4 cells/ml [IQR] 84 [53–173] 161 [54–261] 0.04
Hydrocephalus (CT/MRI)
Yes/no 17/13 (56.7/43.3) 10/13 (43.5/56.5) 0.3
CSF parameters Definite TBM
{ Non TBM
{ P value
Lymphocytes (cells/ml) 99 [16–42] 28 [10–82] 0.01
Neutrophils (cells/ml) 67 [20–134] 9 [0–66] 0.002
Protein g/l 1.8 [1.14–2.7] 1.0 [0.8–1.9] ,0.001
CSF Glucose mmol/l 1 [1.0–1.7] 2.1 [1.5–2.7] ,0.001
CSF: serum Glucose ratio 0.2 [0.16–0.3] 0.4 [0.2–0.5] ,0.001
Lymphocytes: total ratio 0.6 (0.2–0.8) 0.8 (0.2–1.0) 0.2
*We chose a 36 year and 6 day cut off as this was a significant discriminator.
between acute septic and aseptic meningitis [9].
BA (Black African), M (mixed race), E (European), I (Indian).
P (positive), N (negative).
{= Median and inter-quartile ranges.
doi:10.1371/journal.pone.0015664.t001
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[12], are expensive, and not widely available in high TB and HIV
burden settings, smear microscopy remains the only diagnostic test
that can rapidly and confidently establish a diagnosis of TBM.
Thus, although at first glance, the LAM sensitivity of 31% may
seem modest the high specificity confers rule-in value enabling a
rapid diagnosis in approximately a third more of patients than
could have been obtained with microscopy. Furthermore, in HIV-
infected persons with a CD4 count of less than 100 cells/ml the
sensitivity rose to 50%. Several studies have now confirmed the
rule-in utility of the LAM ELISA in HIV co-infected subjects with
advanced immunosuppresion when using urine samples
[19,21,24,25,32,33]. These studies have also confirmed that urine
LAM positivity is associated for HIV positivity and advanced
immunosuppresssion characterised by low CD4 counts [19,24,32].
Similarly, we confirm that in CSF LAM positivity is associated
with a positive HIV status and low CD4 count. We hypothesise
that HIV-infected patients, particularly those with advanced
immunosuppression, have a higher mycobacterial load and hence
higher levels on LAM antigen in body fluids [24].
These results are of considerable significance given that a POC
lateral flow format of the LAM assay is now at a finalised
prototype stage and available for clinical trials [21]. This POC
format now requires optimisation using CSF given that the assay
was designed for use with urine samples.
A clinical prediction rule using laboratory parameters widely
available in resource-poor high HIV prevalence settings had rule-
in value similar to that of the LAM assay. An existing clinical
prediction rule has been developed by Thwaites and colleagues
but was tailored to diagnose bacterial rather than TB meningitis
[9]. Similarly, two other studies in resource-poor settings identified
a week long history, CSF cell count of ,1000 cells/mm
3,
predominant lymphocytosis, and focal deficits as predictive for
TBM [34,35]. These studies sought to distinguish bacterial and
TBM, rather than distinguishing between causes of aseptic
meningitides. More recently, case definitions for TBM in high
burden settings have been proposed [36]. We applied these
definitions to our probable TB group. This categorised patients as
probable TBM (64%; based on the proposed definition as outlined
in [36]) and as possible TBM (35%; based on the proposed
definition as outlined in [36]). When our scoring system was
combined with the LAM assay the rule-in value significantly
improved to ,65%. Thus, if the POC version of the LAM assay is
combined with the prediction rule then this could likely enable the
rapid diagnosis of definite TBM in more than two thirds of HIV
co-infected patients in an African setting. Preliminary data suggest
that the POC LAM assay has equivalent sensitivity to the ELISA
version when using urine samples [21]. The assay now requires
testing in CSF.
Albeit below our ROC-derived cut-point of 0.18 LAM antigen
was nevertheless detected in 19 patients in the non-TBM group
(14 cryptococcal meningitis and 5 viral meningitides). Seven
patients in this group had culture proven dual infection, i.e.
tuberculous and cryptococcal meningitis, which is well document-
ed in HIV-infected patients [37]. In the remaining 12 patients the
possibility of concomitant TB infection cannot be excluded with
certainty and thus misclassification bias may explain the detection
of LAM antigen, at least, in some of these patients. Although
comprehensive follow-up was not available, these patients were
observed as in-patients for a period of 7 to 10 days for
Table 2. Performance outcomes (sensitivity, specificity, predictive values and accuracy) of the LAM ELISA (95% CI), at different cut-
points in the definite TBM and non-TBM groups, using CSF.
2A. Definite TBM (n=39) compared to unselected Non TBM (n=54) AUC
#=0.74 (0.64;0.84)
Cut Point (OD) Sens (CI) Spec (CI) PPV (CI) NPV (CI) Agreement (CI)
$0.1295
* 69% (52;83) 65% (51;77) 59% (43;73) 74% (60;86) 67% (56;76)
$0.148
{ 46% (30;63) 89% (77;96) 75% (53;90) 70% (57;80) 71% (61;80)
$0.18
{ 31% (17;48) 94% (85;99) 80% (52;96) 65% (54;76) 68% (57;77)
2B. Definite TBM (n=39) compared to non TBM (n=35) where non-TB samples were Gram stain or CLAT positive AUC 0.73 (0.61;0.84)
Cut Point (OD) Sens (CI) Spec (CI) PPV (CI) NPV (CI) Agreement (CI)
$0.1295
* 69% (52;83) 63% (45;79) 68% (51;81) 65%(46;80) 66% (54;77)
$0.148
{ 46% (30;63) 86% (70;95) 78% (56;93) 59% (44;72) 65% (53;76)
$0.18
{ 31% (17;48) 94% (81;99) 86% (57;98) 55% (42;68) 61% (49;72)
2C. Definite TBM (n=39) compared to non-TBM (n=19) where non-TB samples were not Gram stain or CLAT positive AUC 0.77=(0.63;0.89)
Cut Point (OD) Sens (CI) Spec (CI) PPV (CI) NPV (CI) Agreement (CI)
$0.1295
* 69% (52;83) 68% (43;87) 82% (65;93) 52% (31;72) 69% (55;80)
$0.148
{ 46% (30;63) 95% (74;100) 95% (74;100) 46% (30;63) 62% (48;74)
$0.18
{ 31% (17;48) 95% (74;100) 92% (64;100) 40% (26;56) 52% (38;65)
(2A) compares the definite TB meningitis (n=39) and unselected non-TB meningitis (n=54) groups. To evaluate whether other concomitantly used rapid tests could
enhance the specificity of the LAM assay the data were also analysed when the non-TB groups were divided into those who had a positive Gram stain or CLAT (2B), or
those non-TBM patients who had a negative Gram stain or CLAT (2C). Each of the tables (2A, 2B, 2C) has results specified using the manufacturer’s cut-point, optimal cut
point using Youdens index and an AUC derived cut point.
*Values expressed as percentages using manufacturers cut point for urine.
{Optimal cut-point as defined by Youden’s index [31].
{Cut points chosen from the ROC curve to derive greater utility of LAM as a rule-in test.
# AUC = Area under the curve.
Sens = sensitivity, Spec = specificity, PPV = positive predictive value, NPV = negative predictive value.
doi:10.1371/journal.pone.0015664.t002
LAM in the Diagnosis of TB Meningitis
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15664Figure 2. Lipoarabinomannan antigen performance outcomes using CSF when comparing definite, probable and non-TB
meningitis groups. (A) shows the definite TBM compared with the unselected non-TB meningitis group and the corresponding ROC curve (B).
Responses when the non-TB meningitis group was stratified by rapid test results (Gram stain or CLAT positive, versus, Gram stain and CLAT both
negative) are shown in (C) with the corresponding ROC curve (D). Note (C) for the sake of clarity does not show the probable TB meningitis group.
doi:10.1371/journal.pone.0015664.g002
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We believe that misclassification bias is unlikely to fully explain our
observations as the same cohort segregated well when the CSF
samples were applied to the antigen-specific ELISPOT test [28].
An alternative explanation might be cross-reactivity with cryptoc-
cocal antigen. Indeed, mannan residues are found in the
crytococcal cell wall [38]. However this possible explanation is
unlikely as there was no change in specificity when cryptococcal
meningitis was excluded from the comparison between definite
and non-TBM groups. Thus, the most likely explanation is cross
reactivity to another antigen, possibly a host-derived lipid antigen,
which is found in high concentrations in the lipid-containing
central nervous system tissue. The sensitivity and specificity is
different in non-lipid containing biological fluids remote from the
site of infection such as urine.
The 12 false negative LAM test results in the definite TBM
group are more difficult to explain. Possibilities include, given the
paucibacillary disease, a low concentration of LAM antigen in the
CSF, which was below the detection limit of the assay, and the
sequestration of LAM antigen in immune complexes despite the
heating step designed to separate LAM-antibody complexes [39].
Previous studies have documented yields of ,60% for smear
microscopy of the CSF after careful examination for 30 minutes
and using high volume processed samples [40]. By contrast, our
study similar to others, performed in a programmatic setting
[6,10,40,41,42,43,44,45,46] detected virtually no positive samples
by smear-microscopy. The high workload (300 microscopy slides
per day) by a single technician with brief microscopic examination
of small volumes of CSF in a ‘real world’ setting prevents
reproduction of yields seen in a research setting [40]. Thus, our
study highlights the difficulty of making a diagnosis of TBM in a
high HIV prevalence setting and the need for new diagnostic tools.
Although lymphocytosis predominates in 85% of patients
[6,7,9,10,35,45,47,48,49,50] a neutrophil predominance may be
seen in the first 10 days [51] (even in HIV co-infected patients
[50,52]), the CSF may be acellular, and the protein levels normal
[47]. Thus a variable picture leaves one uncertain when faced with
a patient requiring empirical therapy.
The limitations of this study are the small sample size and
inadequate follow up of patients to better characterise patients in
terms of diagnosis. However, this study is relatively large
compared to others evaluating diagnostic tools for TBM.
Furthermore, our results are only generalisable to African
populations with a high HIV prevalence, and these results remain
to be confirmed in different geographical settings. Finally, it should
be borne in mind that this commercial assay is optimised for use
using urine samples and its use here represents an off-label
indication. Further studies are now required using an ELISA and
lateral flow assay optimised using CSF samples.
In summary, this study suggests that a standardised LAM
antigen detection assay is a useful rapid rule-in test for TBM in
HIV-infected individuals with advanced immunosuppression.
The test’s rule-in value can be enhanced by combining it with
a clinical prediction rule developed for patients with suspected
TBM from a high TB and HIV prevalence setting. Studies are
now required to confirm these findings in other settings, to
ascertain the value of combining LAM with alternative rapid tests
such as quantitative T cell assays [28], and to clarify the utility of
using a lateral flow point-of-care LAM assay optimised for use
with CSF.
Table 3. LAM performance outcomes in definite TBM and non-TBM patients when stratified by HIV status and CD4 count.
All
(95% CI)
HIV
*
(95% CI)
CD4 [All]
(95% CI)
Negative Positive ,100
{ 100–199
{ $200
#
(n=93) (n=10) (n=81) (n=39) (n=23) (n=31)
Sensitivity
{ 31(17;48) 0% (0;60) 35 (20;53) 50 (27;73) 18 (2;52) 0 (0;37)
Specificity
{ 94 (85;99) 100 (54;100) 96 (86;99) 95 (74;99) 100 (74;100) 91(72;99)
PPV
{ 80 (52;96) N/A 86 (57;98) 91 (59;99) 100 (16;100) 0 (0;84)
NPV
{ 65 (54;76) 60 (26;88) 67 (55;78) 64 (44;81) 57 (34;78) 72 (53;87)
Agreement 68 (57;77) 60 (26;88) 70 (59;80) 72 (55;85) 61 (39:80) 68 (49;83)
*Comparison between HIV positive and HIV negative patients was not significant; p value was 0.3.
{Expressed as percentages.
{Comparison between sensitivity values for CD4 counts ,100 with $100, the p value was 0.01.
#Comparison between sensitivity values for CD4counts ,200 with $200, the p value was 0.03.
Note: HIV status was unknown for 1 patient in the definite TBM group and 1 patient in the non TBM group.
doi:10.1371/journal.pone.0015664.t003
Table 4. Univariable and multivariable analysis for the
prediction of definite TB meningitis.
Characteristic OR 95%CI
p
value
b
coefficient Score
Univariate analysis
Lymphocyte count .200 (cells/ml) 6.5 (2–22) 0.003
Neutrophil count $36 (cells/ml) 5.0 (2–12) ,0.001
Protein Level $2.5 g/l 3.6 (1–10) 0.02
CSF glucose #1 mmol/l 8.4 (3–24) ,0.001
Ratio of CSF/serum glucose #0.2 9.3 (3–28) ,0.001
CD4 count (,200 cells/ml) 2.9 (1–7) 0.03
CLAT test (NEG) 8.7 (3–28) ,0.001
Previous TB (no) 3.1 (1.2–8.0) 0.02
Multivariate analysis
Ratio of CSF/serum glucose #0.2 7.1 (1.8–29) 0.006 2 2
Lymphocyte count .200 (cells/ml) 7.6 (1.5–40) 0.017 2 2
CD4 count (,200cells/ml) 6.8 (1.9–24) 0.003 1.9 2
CLAT test (NEG) 12.9 (3–52) ,0.001 2.6 3
doi:10.1371/journal.pone.0015664.t004
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